Penserra Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Penserra Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76M	Buy	+11,268	New	+$2.44M	0.02%	335
2026 Q1	–	Sell	-10,450	Closed	-$1.91M	–	1094
2025 Q4	$1.91M	Buy	+10,450	New	+$1.46M	0.02%	336
2025 Q2	–	Sell	-19,112	Closed	-$2.23M	–	1031
2025 Q1	$2.23M	Buy	+19,112	New	+$2.18M	0.04%	288
2021 Q4	–	Sell	-865	Closed	-$28K	–	1382
2021 Q3	$28K	Buy	865 +10	+1%	+$390	﹤0.01%	1194
2021 Q2	$57K	Buy	855 +15	+2%	+$900	﹤0.01%	965
2021 Q1	$47K	Sell	840 -15	-2%	-$1.05K	﹤0.01%	822
2020 Q4	$69K	Buy	855 +535	+167%	+$40K	﹤0.01%	645
2020 Q3	$22K	Buy	+320	New	+$24.9K	﹤0.01%	723

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Penserra Capital Management's AXSM Position: Q2 2026 in Review

Penserra Capital Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 11,268 shares worth $2.76M. The stake represents 0.02% of the portfolio and ranks #335 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in AXSM as recently as Q4 2025.

Penserra Capital Management first reported a position in AXSM in Q3 2020 and has held it in 8 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Penserra Capital Management held 11,268 shares of Axsome Therapeutics worth $2.76M as of Q2 2026.
Axsome Therapeutics was a new Penserra Capital Management position in Q2 2026.
Axsome Therapeutics made up 0.02% of Penserra Capital Management's portfolio in Q2 2026, its #335 holding.
Penserra Capital Management first reported a position in Axsome Therapeutics in Q3 2020 and has held it in 8 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.